Axogen prices 4,910,000-share follow-on offering at USD 42.5 per share
AXGN•Use of proceeds
Net proceeds are earmarked primarily to fund cash consideration for the planned BioCircuit Technologies acquisition, with any remainder for general corporate purposes.
Offering priced and terms set
Axogen priced an underwritten public offering of 4,910,000 common shares at USD 42.5 per share.
- Gross proceeds are expected to be about USD 208.7 million, excluding any exercise of the underwriters’ option.
- Underwriters have a 30-day option to buy up to 736,500 additional shares.
- Closing is expected on Sept. 11, 2026, subject to customary closing conditions.
